CHURCHILL MANAGEMENT Corp Has $2.06 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

CHURCHILL MANAGEMENT Corp boosted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXGet Rating) by 4.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,893 shares of the pharmaceutical company’s stock after acquiring an additional 345 shares during the period. CHURCHILL MANAGEMENT Corp’s holdings in Vertex Pharmaceuticals were worth $2,060,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in VRTX. Tudor Investment Corp Et Al acquired a new position in Vertex Pharmaceuticals during the 3rd quarter worth $5,380,000. MML Investors Services LLC lifted its position in Vertex Pharmaceuticals by 1.3% during the 3rd quarter. MML Investors Services LLC now owns 11,133 shares of the pharmaceutical company’s stock worth $2,019,000 after acquiring an additional 143 shares during the last quarter. LPL Financial LLC lifted its position in Vertex Pharmaceuticals by 53.2% during the 3rd quarter. LPL Financial LLC now owns 112,583 shares of the pharmaceutical company’s stock worth $20,421,000 after acquiring an additional 39,081 shares during the last quarter. Two Sigma Securities LLC lifted its position in Vertex Pharmaceuticals by 186.1% during the 3rd quarter. Two Sigma Securities LLC now owns 1,291 shares of the pharmaceutical company’s stock worth $234,000 after acquiring an additional 2,791 shares during the last quarter. Finally, TownSquare Capital LLC acquired a new position in Vertex Pharmaceuticals during the 3rd quarter worth $355,000. 89.84% of the stock is owned by hedge funds and other institutional investors.

In other news, SVP Joy Liu sold 120 shares of the company’s stock in a transaction that occurred on Friday, April 29th. The shares were sold at an average price of $275.41, for a total transaction of $33,049.20. Following the transaction, the senior vice president now directly owns 14,334 shares in the company, valued at $3,947,726.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Kristen Ambrose sold 327 shares of the company’s stock in a transaction that occurred on Monday, April 25th. The stock was sold at an average price of $269.55, for a total transaction of $88,142.85. Following the transaction, the chief accounting officer now owns 3,496 shares in the company, valued at $942,346.80. The disclosure for this sale can be found here. Insiders have sold 36,683 shares of company stock worth $10,227,645 over the last ninety days. Insiders own 0.40% of the company’s stock.

Several research analysts have recently issued reports on the stock. Wells Fargo & Company boosted their price objective on shares of Vertex Pharmaceuticals from $300.00 to $305.00 in a report on Friday, May 6th. StockNews.com assumed coverage on shares of Vertex Pharmaceuticals in a report on Thursday, March 31st. They set a “strong-buy” rating on the stock. Oppenheimer boosted their price objective on shares of Vertex Pharmaceuticals from $305.00 to $350.00 in a report on Monday, April 4th. Cowen boosted their price objective on shares of Vertex Pharmaceuticals from $305.00 to $310.00 in a report on Monday, June 13th. Finally, Maxim Group upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $325.00 price objective on the stock in a report on Wednesday, June 1st. Seven equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $282.61.

Shares of Vertex Pharmaceuticals stock opened at $272.31 on Thursday. The company has a current ratio of 4.75, a quick ratio of 4.60 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $69.64 billion, a price-to-earnings ratio of 28.66, a P/E/G ratio of 1.94 and a beta of 0.55. Vertex Pharmaceuticals Incorporated has a 1-year low of $176.36 and a 1-year high of $292.75. The firm’s 50-day moving average price is $264.63 and its two-hundred day moving average price is $246.16.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Rating) last issued its quarterly earnings data on Thursday, May 5th. The pharmaceutical company reported $3.16 earnings per share for the quarter, missing the consensus estimate of $3.17 by ($0.01). The firm had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.07 billion. Vertex Pharmaceuticals had a return on equity of 32.24% and a net margin of 30.84%. Vertex Pharmaceuticals’s quarterly revenue was up 21.6% compared to the same quarter last year. During the same period in the prior year, the company posted $2.54 earnings per share. As a group, equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 12.47 EPS for the current year.

Vertex Pharmaceuticals Company Profile (Get Rating)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Featured Stories

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXGet Rating).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Want More Great Investing Ideas?

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.